[1] Saito Y, Oyama K, Tsujita K, et al. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond[J]. J Cardiol, 2023, 81(2):168-178.
[2] 马萌雪,马萍,徐清斌,等.急性心肌梗死并发心力衰竭的风险预测模型构建及验证[J].天津医药, 2023, 51(11):1221-1226.
[3] Hendricks S, Dykun I, Balcer B, et al. Higher BNP/NT-pro BNP levels
stratify prognosis equally well in patients with and without heart failure: a meta-analysis[J]. ESC Heart Fail, 2022, 9(5):3198-3209.
[4] 谈昀,马兰香,张树苗,等.急性心肌梗死PCI术后支架内再狭窄患者的CRP,Hcy,CysC,NT-proBNP,LDL-C变化及临床意义[J].海南医学, 2022, 33(14):1799-1802.
[5] Li W, Liu X, Huang C, et al. The loss-of-function mutation of CETP affects HDLc levels but not ApoA1 in
patients with acute myocardial infarction[J]. Nutr Metab Cardiovasc Dis, 2021, 31(2):602-607.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会,《中国循环杂志》编辑委员会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志, 2001, 29(12):710-725.
[7] 傅绪杰,邵建华.Killip分级在老年急性心肌梗死预后判断中的价值[J].中华老年心脑血管病杂志, 2001, 3(4):243.
[8] 肖翔,彭飞,周瑞.血清N端脑钠肽前体,肌红蛋白,D-二聚体水平与冠心病患者心室重构和主要心血管不良事件关系分析[J].陕西医学杂志,2023,52(6):697-700.
[9] 张静,苗鹏飞,史志明,等.血清Gal-3,Hcy与急性心肌梗死患者心力衰竭程度及预后的相关性[J].中南医学科学杂志,2022,50(6):865-868.
[10] Shi J,Wang W,Sun Y,et al.Diagnostic value
of cTnl, NT-pro BNP, and combined tests in acute myocardial infarction patients[J]. Altern Ther Health Med,2023,29(7):412-417.
[11] Oremek GM, Passek K, Holzgreve F, et al. The biomarkers BNP and NT-proBNP[J]. Zentralbl Arbeitsmed
Arbeitsschutz Ergon,2023,73(2):89-95.
[12] Fang CC,Jao YTFN.Combined left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide after sacubitril/valsartan for predicting
outcomes in patients with heart failure with reduced ejection fraction[J]. Acta Cardiol Sin,2023,39(2):297-308.
[13] Ma W,Zhang P,Hu H.Serum levels of Hcy,sST2 and CA-125 in CHF patients and their correlation with cardiac function
classification[J].Heart Surg Forum, 2023,26(5):E449-E454.
[14] Dong XJ,Wang BB,Hou FF,et al.Homocysteine (Hcy) levels in patients with atrial fibrillation (AF):a meta-analysis[J]. Int J Clin Pract,2021,75(12):e14738.
[15] Zhang N,Shi F,Liang H,et al.The feasibility of
using Hcy, CRP, and Cys-C to analyze AMI patients' disease conditions and prognoses[J].Am J Transl Res, 2021,13(4):2724-2730.
[16] Guan J, Wu L, Xiao Q, et al. Levels and
clinical significance of serum homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), vaspin, and visfatin in elderly
patients with different types of coronary heart disease[J].Ann Palliat Med,2021,10(5):5679-5686.
[17] 王玮,张林叶,刘冉.血清Hcy,Cys-C水平与急性心肌梗死患者冠脉病变程度及预后的关系研究[J].湖南师范大学学报(医学版),2022,19(1):206-210.
[18] Li S,Xie X,Zeng X,et al.Serum
apolipoprotein B to apolipoprotein A-I ratio
predicts mortality in patients with heart failure[J].ESC Heart Fail,2024, 11(1):99-111.
[19] Blanchard V,Chemello K,Hollstein T,et al.The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors[J].Cardiovasc Res,2022,118(9):2103-2111.
[20] Cicero AFG,Fogacci F,Derosa G,et al.Lipoprotein(a) serum levels predict pulse wave velocity in subjects in primary
prevention for cardiovascular disease with large Apo(a) isoforms:data from the
brisighella heart study[J]. Biomedicines,2022,10(3):656.
[21] Afanasieva OI,Tyurina AV,Ezhov MV,et al.Lipoprotein(a) and low-molecular-weight apo(a) phenotype as determinants of new cardiovascular events in patients
with premature coronary heart disease[J].Diseases,2023,11(4):145.
[22] 陈磊,刘新灿,王炜,等.急性心肌梗死患者血清N末端脑钠肽前体,载脂蛋白E,载脂蛋白A1,载脂蛋白B水平与冠状动脉病变的关系探究[J].中国临床医生杂志,2022,50(5):550-554.
|